Laurus Labs stock declined by more than 15 per cent on Monday following the U.S. government’s directive to halt the President’s Emergency Plan for AIDS Relief (PEPFAR), which would have disrupted the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback